(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:154242

Synonyms

alpha-D-manno-hexopyranosyl-(1->2)-[beta-D-galacto-hexopyranosyl-(1->3)]-beta-D-gluco-hexopyranose
Man(a1-2)[Gal(b1-3)]b-Glc
WURCS=2.0/3,3,2/[a2122h-1b_1-5][a1122h-1a_1-5][a2112h-1b_1-5]/1-2-3/a2-b1_a3-c1

Definition

References

GlyTouCan:G76150XM

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model